4.8 Article

DOT1L inhibition reveals a distinct subset of enhancers dependent on H3K79 methylation

Journal

NATURE COMMUNICATIONS
Volume 10, Issue -, Pages -

Publisher

NATURE RESEARCH
DOI: 10.1038/s41467-019-10844-3

Keywords

-

Funding

  1. Medical Research Council (MRC, UK) Molecular Hematology Unit grant [MC_UU_12009/6, MR/M003221/1]
  2. Wellcome Trust Strategic Award [106130/Z/14/Z]
  3. Molecular Hematology Unit [MC_UU_12009]
  4. MRC Strategic Award
  5. MRC [MC_UU_12009/11, MC_U137961146, G1000729, MC_UU_12009/6, MR/M003221/1, MC_UU_00016/14, MR/L008963/1, MC_UU_00016/6, MC_UU_12009/15, MC_UU_00016/11, MC_PC_15065] Funding Source: UKRI

Ask authors/readers for more resources

Enhancer elements are a key regulatory feature of many important genes. Several general features including the presence of specific histone modifications are used to demarcate potentially active enhancers. Here we reveal that putative enhancers marked with H3 lysine 79 (H3K79) di or trimethylation (me2/3) (which we name H3K79me2/3 enhancer elements or KEEs) can be found in multiple cell types. Mixed lineage leukemia gene (MLL) rearrangements (MLL-r) such as MLL-AF4 are a major cause of incurable acute lymphoblastic leukemias (ALL). Using the DOT1L inhibitor EPZ-5676 in MLL-AF4 leukemia cells, we show that H3K79me2/3 is required for maintaining chromatin accessibility, histone acetylation and transcription factor binding specifically at KEEs but not non-KEE enhancers. We go on to show that H3K79me2/3 is essential for maintaining enhancer-promoter interactions at a subset of KEEs. Together, these data implicate H3K79me2/3 as having a functional role at a subset of active enhancers in MLL-AF4 leukemia cells.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available